...
search icon
amlx-img

Amylyx Pharmaceuticals Inc Share Price

AMLX
NSQ
$14.07
-$0.28
(-1.95%)
1D
Industry: Pharmaceuticals Sector: Health Care

Amylyx Pharmaceuticals Inc Analyst Forecast

Amylyx Pharmaceuticals Inc Share Price Chart

Amylyx Pharmaceuticals Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.58B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
680.39K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.6 L
$17.49 H
$14.07

About Amylyx Pharmaceuticals Inc, Common Stock

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Amylyx Pharmaceuticals Inc Stock Returns

Time FrameAMLXSectorS&P500
1-Week Return10.47%0.91%2.13%
1-Month Return15.82%-0.72%-0.47%
3-Month Return16.38%2.24%1.29%
6-Month Return75%19.1%7.71%
1-Year Return306.52%7.15%14.7%
3-Year Return-59.98%16.96%67.75%
5-Year Return-20.59%33.23%76.25%

Amylyx Pharmaceuticals Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue650.00K285.00K22.23M380.79M87.37M[{"date":"2020-12-31","value":0.17,"profit":true},{"date":"2021-12-31","value":0.07,"profit":true},{"date":"2022-12-31","value":5.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":22.94,"profit":true}]
Cost of Revenue24.59M52.00K2.99M25.44M42.16M[{"date":"2020-12-31","value":58.34,"profit":true},{"date":"2021-12-31","value":0.12,"profit":true},{"date":"2022-12-31","value":7.1,"profit":true},{"date":"2023-12-31","value":60.35,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(23.94M)285.00K19.24M355.35M45.22M[{"date":"2020-12-31","value":-6.74,"profit":false},{"date":"2021-12-31","value":0.08,"profit":true},{"date":"2022-12-31","value":5.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":12.72,"profit":true}]
Gross Margin(3683.69%)100.00%86.54%93.32%51.75%[{"date":"2020-12-31","value":-3683.69,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.54,"profit":true},{"date":"2023-12-31","value":93.32,"profit":true},{"date":"2024-12-31","value":51.75,"profit":true}]
Operating Expenses15.06M82.69M220.58M316.54M359.95M[{"date":"2020-12-31","value":4.18,"profit":true},{"date":"2021-12-31","value":22.97,"profit":true},{"date":"2022-12-31","value":61.28,"profit":true},{"date":"2023-12-31","value":87.94,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(39.01M)(82.69M)(201.34M)38.80M(314.73M)[{"date":"2020-12-31","value":-100.52,"profit":false},{"date":"2021-12-31","value":-213.1,"profit":false},{"date":"2022-12-31","value":-518.89,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-811.12,"profit":false}]
Total Non-Operating Income/Expense(5.55M)(5.21M)8.03M31.65M26.40M[{"date":"2020-12-31","value":-17.53,"profit":false},{"date":"2021-12-31","value":-16.45,"profit":false},{"date":"2022-12-31","value":25.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":83.42,"profit":true}]
Pre-Tax Income(42.28M)(87.93M)(197.60M)54.30M(302.14M)[{"date":"2020-12-31","value":-77.87,"profit":false},{"date":"2021-12-31","value":-161.94,"profit":false},{"date":"2022-12-31","value":-363.93,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-556.45,"profit":false}]
Income Taxes2.56M(52.00K)774.00K5.03M(393.00K)[{"date":"2020-12-31","value":50.88,"profit":true},{"date":"2021-12-31","value":-1.03,"profit":false},{"date":"2022-12-31","value":15.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-7.82,"profit":false}]
Income After Taxes(44.84M)(87.88M)(198.38M)49.27M(301.74M)[{"date":"2020-12-31","value":-91,"profit":false},{"date":"2021-12-31","value":-178.36,"profit":false},{"date":"2022-12-31","value":-402.62,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-612.42,"profit":false}]
Income From Continuous Operations(42.28M)(87.93M)(198.38M)49.27M(301.74M)[{"date":"2020-12-31","value":-85.81,"profit":false},{"date":"2021-12-31","value":-178.46,"profit":false},{"date":"2022-12-31","value":-402.62,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-612.42,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(42.28M)(87.88M)(198.38M)49.27M(301.74M)[{"date":"2020-12-31","value":-85.81,"profit":false},{"date":"2021-12-31","value":-178.36,"profit":false},{"date":"2022-12-31","value":-402.62,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-612.42,"profit":false}]
EPS (Diluted)-(7.96)(3.43)0.70(2.47)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1137.14,"profit":false},{"date":"2022-12-31","value":-490,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-352.86,"profit":false}]

Amylyx Pharmaceuticals Inc Ratios

Amylyx Pharmaceuticals Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

AMLX
Cash Ratio 13.34
Current Ratio 13.70

Amylyx Pharmaceuticals Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AMLX
ROA (LTM) -39.44%
ROE (LTM) -56.53%

Amylyx Pharmaceuticals Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AMLX
Debt Ratio Lower is generally better. Negative is bad. 0.08
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.92

Amylyx Pharmaceuticals Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AMLX
Trailing PE NM
Forward PE 2.77
P/S (TTM) 4.44
P/B 4.75
Price/FCF NM
EV/R 6446.63
EV/Ebitda NM

FAQs

What is Amylyx Pharmaceuticals Inc share price today?

Amylyx Pharmaceuticals Inc (AMLX) share price today is $14.07

Can Indians buy Amylyx Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Amylyx Pharmaceuticals Inc (AMLX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AMLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Amylyx Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Amylyx Pharmaceuticals Inc (AMLX) via the Vested app. You can start investing in Amylyx Pharmaceuticals Inc (AMLX) with a minimum investment of $1.

How to invest in Amylyx Pharmaceuticals Inc shares from India?

You can invest in shares of Amylyx Pharmaceuticals Inc (AMLX) via Vested in three simple steps:

  • Click on Sign Up or Invest in AMLX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Amylyx Pharmaceuticals Inc shares
What is Amylyx Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Amylyx Pharmaceuticals Inc (AMLX) is $17.49. The 52-week low price of Amylyx Pharmaceuticals Inc (AMLX) is $2.6.

What is Amylyx Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Amylyx Pharmaceuticals Inc (AMLX) is

What is Amylyx Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Amylyx Pharmaceuticals Inc (AMLX) is 4.75

What is Amylyx Pharmaceuticals Inc dividend yield?

The dividend yield of Amylyx Pharmaceuticals Inc (AMLX) is 0.00%

What is the Market Cap of Amylyx Pharmaceuticals Inc?

The market capitalization of Amylyx Pharmaceuticals Inc (AMLX) is $1.58B

What is Amylyx Pharmaceuticals Inc's stock symbol?

The stock symbol (or ticker) of Amylyx Pharmaceuticals Inc is AMLX

How Can Investors Use Amylyx Pharmaceuticals Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Amylyx Pharmaceuticals Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Amylyx Pharmaceuticals Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Amylyx Pharmaceuticals Inc shares for Indian investors?

When investing in Amylyx Pharmaceuticals Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Amylyx Pharmaceuticals Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Amylyx Pharmaceuticals Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Amylyx Pharmaceuticals Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Amylyx Pharmaceuticals Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top